Subunit

A subunit is one of the individual protein chains that join together to form a larger, functional receptor or ion channel. Most receptors are not built from a single molecule; they are assembled from two, four, or five protein subunits that lock together into a working complex. Which subunits a cell uses — and in what combination — determines the shape of the binding sites, the electrical properties of the channel, and which drugs can influence it.

The concept matters because the same receptor family can take on many different pharmacological identities depending on subunit composition. Two neurons can both express GABA-A receptors while responding quite differently to drugs, because they assembled their receptors from different subunit variants.

How it works · its role

Each subunit is a protein that folds into a defined three-dimensional shape and contributes a portion of the finished receptor's structure. In pentameric receptors — those built from five subunits, like the GABA-A receptor — each chain supplies one segment of the central ion pore and one face of a binding region.

Binding sites for drugs and neurotransmitters typically sit at the interfaces between adjacent subunits. Because those interfaces depend on which subunit types are present, changing the subunit composition reshapes the binding pocket. A benzodiazepine, for example, binds at the junction between the α and γ subunits of the GABA-A receptor; substituting a δ subunit for γ removes that binding site entirely.

Subunit composition also governs channel kinetics: how quickly a channel opens, how long it remains open, and how readily it enters a desensitized state that no longer responds to its ligand.

Relevance to substances & effects

The GABA-A receptor offers the clearest example of subunit logic in substance pharmacology. Its five subunits are drawn from a large family of variants — α1 through α6, several β and γ types, plus δ and others — and most receptors hold two α, two β, and one γ or δ subunit.

The α variant present predicts much about a drug's profile: receptors containing α1 are linked to sedation and amnesia; those with α2 or α3 to anxiety suppression and muscle relaxation. This is why researchers have long sought benzodiazepine-site compounds selective for certain α types, aiming to separate sleep-induction from anxiety relief.

NMDA receptors, targets for dissociatives such as ketamine and phencyclidine, are built from GluN1 subunits paired with GluN2 variants (A through D). The GluN2 type present shapes how strongly the channel is blocked by these drugs and how readily they enter the pore. Nicotinic acetylcholine receptors — the primary target of nicotine — assemble from α and β combinations that shift tissue distribution and sensitivity across the body.

Chronic exposure to substances acting at these receptors can drive changes in which subunits cells produce, gradually retuning the receptor population. Prolonged benzodiazepine use, for example, is associated with shifts in GABA-A subunit expression that reduce the receptor's sensitivity to its own ligands — one cellular basis for tolerance, and part of why withdrawal from sedative-hypnotics can be physiologically difficult.